Delving into the Latest Updates on MSC Secretome Eye Drops(University of Illinois) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome(University of Illinois)

Target-

Action-

Mechanism

Stem cell replacements

Therapeutic Areas

Eye Diseases

Active Indication

Corneal epithelial degenerationPersistent corneal epithelial defectCorneal defect+ [1]

Inactive Indication-

Originator Organization

University of Illinois

Active Organization

University of Illinois

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.

Start Date01 Aug 2025

Sponsor / Collaborator

University of Illinois

[+2]

NCT05204329

/ CompletedEarly Phase 1IIT

Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of topical MSC Secretome eye drops. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use anterior segment Optical Coherence Tomography (OCT)/Scheimpflug Imaging, esthesiometry, and visual analogue scale (VAS) to assess treatment tolerability.

Start Date24 Jan 2024

Sponsor / Collaborator

University of Illinois

[+2]

100 Clinical Results associated with MSC Secretome Eye Drops(University of Illinois)

Login to view more data

100 Translational Medicine associated with MSC Secretome Eye Drops(University of Illinois)

Login to view more data

100 Patents (Medical) associated with MSC Secretome Eye Drops(University of Illinois)

Login to view more data

100 Deals associated with MSC Secretome Eye Drops(University of Illinois)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Corneal epithelial degeneration	Phase 2	United States	University of Illinois	01 Aug 2025
Persistent corneal epithelial defect	Phase 2	United States	University of Illinois	01 Aug 2025
Corneal defect	Phase 1	United States	University of Illinois	24 Jan 2024
Corneal epithelial defect	Phase 1	United States	University of Illinois	24 Jan 2024